In this study, patients with advanced non-small cell lung cancer (NSCLC) with EGFR/ALK wild type (WT) and PDL1 expression ≥ 1%, according to tumor proportion (TPS) score, received the combination of tiragolumab plus atezolizumab vs. atezolizumab alone. This evidence concerns the gene ALK and non-small cell lung carcinoma.